Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for InflaRx N.V. (IFRX : NSDQ)

• Company Description    InflaRx N.V. is a clinical-stage biopharmaceutical company. It focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. InflaRx N.V. is based in Germany. Number of Employees: 65

• Price / Volume Information    Yesterday's Closing Price: $2.61 Daily Weekly Monthly 20 Day Moving Average: 3,349,862 shares Shares Outstanding: 72.29 (millions) Market Capitalization: $188.68 (millions) Beta: 2.42 52 Week High: $2.95 52 Week Low: $0.71 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 67.31% 59.13% 12 Week 180.25% 159.08% Year To Date 158.42% 124.84%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL WINZERLAER STR. 2 - JENA,2M 07745 DEU ph: 49-36-4150-8180 fax: 49-36-4150-8181 ir@inflarx.com http://www.inflarx.de

• General Corporate Information    Officers Niels Riedemann - Chief Executive Officer Nicolas Fulpius - Chairman Thomas Taapken - Chief Financial Officer Derval O'Carroll - Senior Vice President Mark Kubler - Director Peer Information InflaRx N.V. (CORR.) InflaRx N.V. (RSPI) InflaRx N.V. (CGXP) InflaRx N.V. (BGEN) InflaRx N.V. (GTBP) InflaRx N.V. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: N44821101 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/06/26 Share - Related Items Shares Outstanding: 72.29 Most Recent Split Date: (:1) Beta: 2.42 Market Capitalization: $188.68 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.13 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.51 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/06/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 4.37 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 35.71% vs. Previous Quarter: 47.06% Sales Growth vs. Year Ago Period: -79.41% vs. Previous Quarter: -37.78% ROE 03/31/26 - -88.30 12/31/25 - -80.51 09/30/25 - -63.72 ROA 03/31/26 - -65.77 12/31/25 - -61.36 09/30/25 - -49.40 Current Ratio 03/31/26 - 4.16 12/31/25 - 4.13 09/30/25 - 3.33 Quick Ratio 03/31/26 - 4.16 12/31/25 - 4.13 09/30/25 - 3.06 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - -149,706.05 12/31/25 - -155,539.73 09/30/25 - -61,241.09 Book Value 03/31/26 - 0.60 12/31/25 - 0.65 09/30/25 - 0.78 Inventory Turnover 03/31/26 - 2.82 12/31/25 - 1.74 09/30/25 - 0.88 Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00

Powered by Zacks Investment Research ©